The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Gober's campaign was predominantly self-financed. From October 14, 2025, through the March 3, 2026 primary, his campaign reported $2,265,179.06 in receipts, of which $1,524,821.91, or approximately 67.3%, came from Gober himself through candidate loans and contributions. Of the remaining $740,357.15 in non-self-funded receipts, $374,365.91 was associated with addresses within the district, while $148,595.74 came from Texas addresses outside the district and $217,395.50 came from addresses outside Texas.
Beginning in the 11th century, European soldiers and knights relied on chain mail for protection of their bodies, and chain armor "shirts" with wide sleeves that hung to the elbow were common. However, it wasn't until the 12th century that chain mail shirts with longer, narrower sleeves began to be worn, and these on occasion had chain mail mittens or "muffs" resembling fingerless gloves and with a pocket for the thumb (though some of these did have complete fingers as well). These attached at the lower edge of the sleeve, and protected the wearer's hands from cuts and lacerations during combat but offered no protection against crushing blows. It wasn't until the early 14th century that armorers began to design fully articulated plate armor: along with this development of the use of plates as a means of protecting the body from blows was the development of hand protection in the form of gauntlets made of overlapping plates of steel. These were created both in the fingerless "mitten" style (which offered plate armor protection and allowed the fingers to share heat but limited the wearer's ability to move those fingers) as well as the fully fingered "glove" style (which though still ungainly and less comfortable in cold weather, permitted full use of all of the fingers). A variety of gauntlet called a "demi-gauntlet" or "demi-gaunt" also came into use around this time. A demi-gaunt is a type of plate armour gauntlet that only protects the back of the hand and the wrist: demi-gaunts are worn with gloves made from chain mail or padded leather.
== Function == Fibromodulin participates in the assembly of the collagen fibers of the extracellular matrix. It binds to the same site on the collagen type I molecule as lumican. It also inhibits fibrillogenesis of collagen type I and collagen type III in vitro. It regulates TGF-beta activities by sequestering TGF-beta into the extracellular matrix.
Sources: en.wikipedia.org
== History == The backdoor pathway to DHT biosynthesis was discovered in early 2000s in the marsupials and later confirmed in humans. That is why the backdoor pathway of DHT biosynthesis from 17OHP can be called a marsupial pathway. This pathway is also present in other mammals, such as rats, and are studied in the other mammals as a way to better understand these pathways in humans. Marsupials, and in particular, tammar wallabies (Notamacropus eugenii) are especially useful for studying the processes of sexual differentiation and development in the context of androgen biosynthesis, because sexual differentiation in these species occurs only after birth, with testes beginning to form two days after birth and ovaries only on the eighth day after birth. This feature of post-natal early sexual differentiation allows scholars to study the influence of hormones on the body from the very beginning of the process of sexual differentiation, as well as the pathways of biosynthesis of these hormones. Tammar wallabies are particularly interesting due to the fact that all these hormones, pathways, and the ways in which hormones affect body features and growth of different organs can be studied when the organism is already born, unlike in other mammals such as rats, where sexual differentiation in a fetus occurs inside the placenta before birth.
=== Photodynamic (PDT) mechanism === PDT can induce many cellular pathways, and its main purpose is to induce cell death, either by apoptosis or necrosis. The fundamental process of photodynamic reactions involves three elements: photosensitizers (PS), light of a specific wavelength, and oxygen present in the cell. The interaction of these three components produced a desirable effect inside targeted tissues. Apart from light and oxygen, photosensitizers are compounds designed to absorb light at particular wavelengths during therapy, which enables them to initiate therapeutic processes. Two pathway branches interact and contribute to different ratios during PDT therapy, affecting its efficiency. Both mechanisms have the same first stage. When cells absorb photosensitizers and are exposed to light that aligns with their absorption spectrum, these substances photo-excite from their stable ground state (S°) to an energised excited singlet state (S1). Some energy is emitted as fluorescence, remaining energy directs the photosensitizer molecule into triplet state T1. Type I pathway of photodynamic reaction: T1 state PS can then interact with nearby molecules. Energy transfers between the photosensitizer and other molecules in the form of hydrogen and electrons, resulting in the creation of free radicals and anion radicals. These radicals remain in ground state and react with oxygen, leading to the formation of reactive oxygen species (ROS) and superoxide anion radicals (O2•−), which further react with oxygen to generate ROS.
=== Observed markers of dedifferentiation === For dedifferentiation, genes in the extracellular matrix play an important role. For example, MMP, the matrix metalloproteinase, has shown up-regulated activity during early stages of limb regeneration. Matrix Metalloproteinases are responsible for degradation of both non-matrix and matrix proteins. MMP degrades proteins in the extracellular matrix of a cell, resulting in the destabilization of the differentiated cell identity. However, the markers selected to represent dedifferentiation can differ according to the tissue and cell types that are being studied. For example, in mice myotubes, dedifferentiation is marked by a decreased expression of Myogenin, a protein present in differentiated myotubes.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.